Additional analysis of Teffect subgroups in HT patients showed that the proportion of CD45RO+ Teffect in CD4+T cells was significantly enhanced (46.65 ± 11.11 vs. 35.25 ± 11.47, P < 0.0001, Figure 2(e)), but conversely CD45RO−Teffect was reduced compared to HC (46.96 ± 11.43 vs. 58.98 ± 11.58, P < 0.0001, Figure 2(f)). This evidence concerns the gene CD4 and hematocrit.